| | Year of publication and first author | Number of cases | Age (years) | Method | Intervention course (d) | Outcome measures | Jadad score (points) | | Control group | Experimental group | Control group | Experimental group | Control group | Experimental group |
| | Tan Yong in 2013 | 38 | 38 | 61.70 ± 9.80 | Gemcitabine 1,000 mg, intravenous drip, once daily, d1–8 + cisplatin 25 mg/m2, intravenous drip, once daily, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 7.50 mg/m2, 0.9% sodium chloride injection 500 ml, intravenous drip, once a day, d1–14 | 21 | (1) (2) (3) (4) (5) | 3 | | Xie Yanru in 2009 | 26 | 22 | 44.00–71.00 | 44.00–69.00 | Gemcitabine 1,000 mg, D1, D8 + cisplatin 75 mg/m2, divided into three days | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride injection 500 ml, intravenous drip, d1–14 | 21 | (1) (2) (3) (4) (5) | 2 | | Chen Yongxing in 2010 | 25 | 30 | 49.00 ± 3.00 | 50.00 ± 2.00 | Gemcitabine 1,000 mg, IV, D1, D8 + cisplatin 25 mg/m2, IV, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, added with 0.9% sodium chloride solution 500 ml, intravenous drip, d1–14 | 21 | (1) (2) (3) (4) (5) | 1 | | Gu Ying in 2010 | 33 | 27 | 53.60 | Gemcitabine 1,000 mg/m2, D1, D8 + cisplatin 25 mg/m2, intravenous drip, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, added with 0.9% sodium chloride solution 500 ml, intravenous drip, d1–14 | 21 | (1) (2) (3) (4) (5) | 1 | | Guo Hongbin in 2010 | 38 | 38 | 55.00 ± 12.00 | 53.00 ± 14.00 | Gemcitabine 1,000 mg/m2, intravenous drip, D1, D8 + cisplatin 30 mg/m2, intravenous drip, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, intravenous drip, d1–14 | 21 | (1) (2) (3) (4) | 2 | | Wei Qihong in 2010 | 16 | 16 | 59.80 | Gemcitabine 1 g/m2, intravenous drip, D1, D8 + cisplatin 30 mg/m2, intravenous drip, d2–4 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, intravenous drip, once a day, d1–14 | 21 | (1) (2) (3) (4) (5) | 2 | | Xu Jian in 2010 | 20 | 20 | 64.00 | Gemcitabine 1,000 mg/M2 + cisplatin 30 mg/m2, tumor target artery perfusion, D1, gemcitabine 1,000 mg/m2, IV, D8, 0.9% sodium chloride injection 500 ml, intravenous drip, D2–12 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg/D, 0.9% sodium chloride injection 500 ml, intravenous drip, 2–12 days | 36 | (1) (2) (3) (4) (5) | 2 | | Chen Qun in 2011 | 35 | 33 | 65 | 63 | Gemcitabine 1,000 mg/m2, intravenous drip, D1, D8 + cisplatin 80 mg/m2, intravenous drip, D1 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride solution 500 ml, intravenous drip, d1–14, intermittent for 7 days | 21 | (1) (2) (3) (4) (5) | 1 | | Ruan Mei in 2011 | 19 | 17 | 58.50 | Gemcitabine 1,000 mg/m2, D1, D8 + cisplatin 75 mg/m2, divided into three days | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride injection 500 ml, intravenous drip, d1–14 | 21 | (1) (2) (3) (4) (5) | 1 | | Wang Fen in 2011 | 29 | 31 | 55.00 | 56.00 | Gemcitabine 1,000 mg/m2, IV, D1, D8 + cisplatin 75 mg/m2, IV, D1 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride solution 500 ml, intravenous drip, d1–14, intermittent for 7 days | 21 | (1) (2) | 1 | | Zheng Qingping in 2011 | 18 | 17 | 54.50 | 50.10 | Gemcitabine 1,000 mg/m2, intravenous drip, D1, D8 + cisplatin 20 mg/m2, intravenous drip, D1–5 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg/D, intravenous drip, d1–14 | 21–28 | (1) (2) (5) | 1 | | Chen Bing in 2012 | 26 | 27 | 56.50 ± 7.30 | 55.70 ± 8.60 | Gemcitabine 1,000 mg/m2, 0.9% sodium chloride injection 100 ml, intravenous drip, D1, D8 + cisplatin 25 mg/m2, 0.9% sodium chloride injection 500 ml, intravenous drip, d2–4 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, intravenous drip, once a day, d1–14 | 14 | (1) (2) (3) (4) (5) | 1 | | He Rong in 2012 | 32 | 40 | 69.80 ± 5.50 | 70.50 ± 5.30 | Gemcitabine 1,000 mg/m2, D1, D8 + cisplatin 30 mg/m2, d2–4 | The control group was treated with the chemotherapy + recombinant human endostatin 7.50 mg/m2, d1∼14 | 21 | (1) (2) (5) | 1 | | Liu Jianwu in 2012 | 30 | 30 | 56.00 | 58.00 | Gemcitabine 1,000 mg/m2, IV, D1, D8 + cisplatin 75 mg/m2, IV, D1, D2 | The control group was treated with the chemotherapy + recombinant human endostatin 15 mg, D1–7 | 21 | (1) (2) (3) (4) (5) | 2 | | Luan Wenqiang in 2012 | 27 | 25 | 40.00–67.00 | 42.00–68.00 | Gemcitabine 1,250 mg/m2, IV, D1, D8 + cisplatin 75 mg/m2, IV, D1 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 75 mg/m2, added with 0.9% sodium chloride solution 500 ml, intravenous drip, d1–14 | 21 | (1) (2) | 1 | | Yin Feng in 2012 | 90 | 94 | 49.30 ± 4.50 | 48.30 ± 5.20 | Gemcitabine 1,000 mg/m2, intravenous drip, D1, d8 + cisplatin 30 mg/m2, intravenous drip, d2–4 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride injection 500 ml, intravenous drip, once a day, d1–14 | 21 | (1) (2) (5) | 1 | | Almu Jiang in 2013 | 40 | 40 | 59.20 ± 9.50 | 58.30 ± 9.60 | Gemcitabine 1.00 mg/m2, 0.9% sodium chloride injection 250 ml, intravenous drip, D1, D14 + cisplatin, 0.9% sodium chloride injection 500 ml, intravenous drip, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride injection 500 ml, intravenous drip, d1–14 | 21 | (1) (2) (3) (4) (5) | 2 | | Zhang Yuanyuan in 2014 | 28 | 31 | 54.00 | 53.00 | Gemcitabine 1,000 mg/m2, D1, D8 + cisplatin 75 mg/m2, divided into three days | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride injection 250 ml, intravenously pumped, d1–9 | 21 | (1) (2) (3) (4) (5) | 2 | | Fu Hao in 2015 | 28 | 32 | 55.81 | 56.21 | Gemcitabine 1,000 mg/m2, intravenous drip, D1, D8 + cisplatin 25 mg/m2, intravenous drip, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride injection 500 ml, intravenous drip, d1–14, intermittent for 7 days | 21 | (1) (2) (3) (4) (5) | 2 | | Liu Tao in 2015 | 32 | 32 | No explanation | Gemcitabine 1,000 mg/m2, intravenous drip, D1, D8 + cisplatin 80 mg/m2, intravenous drip, D1, D2 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, added with 0.9% sodium chloride injection 500 ml, d1–14, repeated intermittently for 7 days | 21 | (1) (2) | 2 | | Li Lihua in 2016 | 23 | 23 | 52.30 ± 10.60 | Gemcitabine 1,000 mg/m2, intravenous drip, D1, D8 + cisplatin 30 mg/m2, intravenous drip, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride solution 500 ml, intravenous drip, d1–14, intermittent for 7 days | 21 | (1) (2) (3) (4) (5) | 3 | | Fangli in 2017 | 23 | 23 | 52.00 | 60.00 | Gemcitabine 1,000 mg/m2, intravenous drip, D1, D8 + cisplatin 75 mg/m2, intravenous drip, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 7.5 0 mg/m2, 0.9% sodium chloride injection 500 ml, once a day, d1–14 | 21 | (1) (2) | 2 | | Jia Xiaoqiong in 2017 | 20 | 20 | 50.00 ± 2.00 | Gemcitabine 1.00 mg/m2, 0.9% sodium chloride injection 150 ml, intravenous drip, D1, D8 + cisplatin 25 mg/m2, 0.9% sodium chloride injection 500 ml, intravenous drip, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 30 mg, 0.9% sodium chloride injection 110 ml, D1–7 | 21 | (1) (2) (3) (4) (5) | 2 | | Xu Li in 2017 | 30 | 30 | 54.10 ± 11.30 | Gemcitabine 1.00 g/m2, 0.9% sodium chloride injection 250 ml, intravenous drip, D1, D8 + cisplatin 30 mg/m2, 0.9% sodium chloride injection 500 ml, intravenous drip, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride injection 500 ml, intravenous drip, d1–14 | 21 | (1) (2) (3) (4) (5) | 3 | | Song Wencan in 2018 | 30 | 30 | 61.70 | 57.40 | Gemcitabine 1,250 mg/m2, intravenous drip, D1, D8 + cisplatin 25 mg/m2, intravenous drip, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg/m2, intravenous drip, D1–7 | 21 | (1) (2) (3) (4) (5) | 1 | | Wang Zhifeng in 2018 | 30 | 34 | 55.45 | 55.97 | Gemcitabine 1,000 mg/m2, 0.9% sodium chloride injection 100 ml, intravenous drip, D1, D2 + cisplatin 75 mg/m2, 0.9% sodium chloride injection 500 ml, intravenous drip, divided into 3 days | The control group was treated with the chemotherapy regimen + recombinant human endostatin 15 mg, 0.9% sodium chloride injection 250 ml, intravenously pumped, d1–9 | 21 | (1) (2) (3) (4) (5) | 1 | | Zhong Li in 2018 | 25 | 25 | 70.34 | 70.21 | Gemcitabine 1,000 mg/m2, 150 ml of 0.9% sodium chloride injection, intravenous drip, D1, d8 + cisplatin 30 mg/m2, 0.9% sodium chloride injection 500 ml, intravenous drip, D1–3 | The control group was treated with the chemotherapy regimen + recombinant human endostatin 7.50 mg/m2, 0.9% sodium chloride injection 100 ml, intravenous drip, d1–14 | 21 | (1) (2) (3) (4) (5) | 2 |
|
|
